Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study
Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, Xiang Gao · 2023
Read Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study by Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, Xiang Gao (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10711459.txt.
Description
Yang and coauthors compare two biologic drugs for Crohn disease in China. Both drugs work well, yet no head-to-head trial exists. The team used real clinic data from six centers. Patients got one drug or the other for gut disease.
The pool held 536 patients treated from 2020 to 2023. Most, 386 in all, got the first drug. Scores tracked remission free of steroids at set weeks. Week 26 and week 52 gave the main check points. Weighting balanced traits between the two drug groups. After that fix, the first drug led on most marks.
Catalog record
| CREATOR | Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, Xiang Gao |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |